SCHEDULE: Cormorant Asset Management Increases Stake in Rapport Therapeutics
Beneficial Ownership Filing
Cormorant Asset Management, LP and Bihua Chen report beneficial ownership of 5.12% of Rapport Therapeutics, Inc. common stock.
Summary
- Cormorant Asset Management, LP and Bihua Chen have filed a Schedule 13G, indicating their beneficial ownership of Rapport Therapeutics, Inc. common stock.
- The filing states that Cormorant Asset Management, LP, as an investment adviser to certain funds, and Bihua Chen collectively beneficially own 2,457,521 shares.
- This represents 5.12% of the total outstanding shares of common stock.
- The filing is an amendment (Amendment No. 6) to a previous Schedule 13G.
- The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without new strategic or financial information.
Positives
- Cormorant Asset Management, LP and Bihua Chen have a significant stake, indicating confidence in Rapport Therapeutics.
- The reporting persons certify that their holdings are in the ordinary course of business, suggesting a non-activist investment approach.
Negatives
- The filing does not provide any new financial performance data or strategic updates for Rapport Therapeutics.
- The increase in ownership, while noted, does not inherently signal positive or negative performance for the company itself.
Risks
- The filing does not explicitly mention any new risks or challenges for Rapport Therapeutics.
- Potential future changes in beneficial ownership by Cormorant Asset Management, LP or Bihua Chen could impact share price volatility.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding Rapport Therapeutics' future performance.
Management Comments
- The filing should not be construed as an admission that any of the reporting persons are, for the purposes of Section 13 of the Act, the beneficial owner of the shares reported herein.
- The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Cormorant Asset Management's continued interest in Rapport Therapeutics, a biotechnology company.
Stakeholder Impact
- Shareholders may view the increased stake by Cormorant Asset Management, LP as a sign of institutional confidence, potentially influencing investor sentiment.
- The filing does not indicate any immediate impact on employees, customers, or suppliers.
Next Steps
- Cormorant Asset Management, LP and Bihua Chen will continue to hold their shares in Rapport Therapeutics, Inc.
- Future filings will be made if beneficial ownership changes significantly.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of previous Schedule 13G filing by the Reporting Persons. |
| 08/05/2026 | Date Rapport Therapeutics, Inc. filed its Quarterly Report on Form 10-Q for the period ended June 30, 2026. |
| 09/30/2026 | Date of Event Which Requires Filing of this Statement (Amendment No. 6). |
| 11/16/2026 | Date of signature for Cormorant Asset Management, LP and Bihua Chen. |
Keywords
Rapport Therapeutics, Cormorant Asset Management, Schedule 13G, Beneficial Ownership, Investment Adviser, Common Stock, Securities Exchange Act
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.